BMS' Bid For Opdivo In First-Line HCC Stymied
Executive Summary
Top-line results from a Phase III study testing Opdivo versus Nexavar in first-line liver cancer fail to meet OS target. Bristol points to positive numerical trend, but the results are a setback in the indication.
You may also be interested in...
AstraZeneca's Imfinzi/Tremelimumab Combo Conquers HIMALAYA
After the combination's success in the non-small cell lung cancer POSEIDON study, AstraZeneca's Imfinzi and tremelimumab could now be on the way to approval as a first-line treatment for hepatocellular carcinoma.
Roche Notches Big IO Win With Tecentriq/Avastin Combo In First-Line HCC
Following quickly on a Bristol trial failure with Opdivo in first-line HCC, Roche’s PD-L1 inhibitor looks poised to be the first immunotherapy approved in the setting, with plans for US, EU and China filings.
BMS Ready To Pounce On Non-Chemo Opportunity In Lung Cancer With Checkmate-227 Data
The Checkmate-227 results surprised with an OS benefit for Opdivo plus Yervoy in first-line NSCLC and a miss for the Opdivo-chemotherapy combination. Bristol reported a solid quarter, with growth for IO, Eliquis.